Ignite Creation Date:
2024-05-05 @ 11:57 AM
Last Modification Date:
2024-10-26 @ 9:16 AM
Study NCT ID:
NCT00180778
Status:
WITHDRAWN
Last Update Posted:
2024-02-26
First Post:
2005-09-13
Brief Title:
Steroids and Antiphospholipid Syndrome- Related Pregnancy Loss
Sponsor:
Imperial College London
Organization:
Imperial College London
Study Overview
Official Title:
Randomised Controlled Trial of Low Dose Steroid Aspirin Heparin Versus AspirinHeparin Amongst Pregnant Women With APS
Status:
WITHDRAWN
Status Verified Date:
2024-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Literature highlighted unnecessary side effects from the relevant combination
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Does the addition of steroids during the first trimester to the standard aspirin heparin treatment reduce the miscarriage rates in women with antiphospholipid antibodies and recurrent first trimester miscarriage in those who had an unsuccessful pregnancy with aspirin heparin
Detailed Description:
Over the last decade the APS has emerged as most important treatable cause of recurrent miscarriages The pathogenesis of fetal loss in this condition is still remains obscure Despite the success of aspirin heparin treatment some pregnant women with APS repeatedly miscarry even on treatment The trial is designed to determine if addition of steroids has an success in these women This is in view of recent in vitro data from our unit reporting that there is an increase decidual cytokine response in APS positive women
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2005-004182-42 | None | None | None |